I think part of the problem with AVH is they have a new product...

I think part of the problem with AVH is they have a new product Recel go waiting on approval from the FDA on May 30. It must be hard trying to sell the "old kit" when the Recell go might be a better option for some clinicians. They'll just wait but agreed it's a mess with AVH although I think the drop is OTT.
EYE on the other hand has a market leading product that is getting excellent feedback, their sales have been increasing fast, are clearly taking market share from their competitors & they're promoting it at the conferences. Totally different scenario IMO it's aggressive but justified.
Time will tell though !!